Therefore, Aβ has been generally recognized as the culprit of AD (Wilcock & Griffin, 2013), which was generated from proteolytic cleavages of APP by the β‐ and γ‐secretases (Querfurth & LaFerla, 2010), and reducing the amount of Aβ might be a potential therapeutic strategy for AD. Here, APP is linked to Alzheimer disease.